MILFORD, Conn.--(BUSINESS WIRE)--Novel Low Temperature PCR Reported in International Journal of Molecular Sciences Milford Hospital announces that Dr. Sin Hang Lee, a Milford Hospital pathologist, and a group of scientists headed by professor Guofan Hong in the State Key Laboratory of Molecular Biology (SKLMB) of the Chinese Academy of Sciences in Shanghai have published a landmark article, entitled “A novel low temperature PCR assured high-fidelity DNA amplification” in the International Journal of Molecular Sciences.
According to the published article, the “novel low temperature (LoTemp) polymerase chain reaction (PCR) catalyzed by a moderately heat-resistant (MHR) DNA polymerase with a chemical-assisted denaturation temperature set at 85 °C instead of the conventional 94–96 °C can achieve high-fidelity DNA amplification of a target DNA, even after up to 120 PCR thermal cycles”; and this technology “has been used to prepare templates for DNA sequencing-based molecular diagnosis of infection caused by Borrelia burgdorferi, human papilloma virus (HPV), Neisseria gonorrhoeae and Chlamydia trachomatis” and “may be useful in performing routine nested PCR to facilitate implementation of DNA sequencing-based diagnostic tests in community hospital laboratories.”
The SKLMB was initially approved by the Chinese State Planning Commission in 1984 and “is focused on the fundamental knowledge related to human diseases and the cutting-edge research systems.”
Low temperature nested PCR was initially developed by Dr. Lee “for DNA sequencing-based molecular diagnosis of infection caused by Borrelia burgdorferi, HPV, Neisseria gonorrhoeae, and Chlamydia trachomatis”. Borrelia burgdorferi is the recognized infective agent of Lyme disease and DNA sequencing can offer reliable diagnosis of Lyme disease at its early phase of infection for timely appropriate treatment of the patients to avoid tissue damages, stated Dr. Lee and his colleagues in a 2010 publication (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2984391/) Milford Medical Laboratory, Inc. will be positioned to offer these DNA sequencing-based molecular diagnostic tests to the patients and physicians.
